LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410

Martin J. van den Bent(Erasmus MC Cancer Institute), Vassilis Golfinopoulos(Champalimaud Foundation), Annemiek Walenkamp(University Medical Center Groningen), Nicolas Whenham(Cliniques Universitaires Saint-Luc), Michael Weller(University Hospital of Zurich), Joana Brilhante(Advantest (Singapore)), Pim J. French(Erasmus MC Cancer Institute), Jim Looman(AbbVie (United States)), Filip De Vos(University Medical Center Utrecht), Sarah Nuyens(European Organisation for Research and Treatment of Cancer), Paul Sanghera(The Edgbaston Hospital), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Marion Smits(Erasmus MC), Marica Eoli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Johan M. Kros(Erasmus MC), Olivier Chinot(Aix-Marseille Université), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Ho‐Jin Lee(Seoul National University Hospital), Jan-Peter de Geus(AbbVie (Netherlands)), Hendrikus J. Dubbink(Erasmus MC), Maarten Spruyt(European Organisation for Research and Treatment of Cancer), Paul M. Clément(Universitair Ziekenhuis Leuven)
Neuro-Oncology
November 1, 2017
Cited by 14


Related Papers